

ASX Release
12 January 2024

ASX Code: MEM

Entitlement Offer Prospectus Shortfall

Pursuant to the pro-rata non-renounceable Entitlement Offer Prospectus dated 4 December 2023 and lodged with ASIC and ASX on same day, the Entitlement Offer closed on 9 January 2024.

A total of 213,227,774 rights to shares were offered under the Entitlement Offer and as at the closing date, 54,305,732 rights to shares were accepted.

The shortfall of 158,922,042 rights to shares are to be placed by the underwriter to the offer, Canaccord Genuity (Australia) Limited.

For further information please contact:

ENDS

For further information, please contact:

Dr David Ali
Interim Managing Director / Chief Executive Officer
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.